ICU Medical (NasdaqGS:ICUI) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Company ParticipantsBrian Bonnell - CFOJayson Bedford - Managing Director of Medical TechnologyJohn Mills - Managing PartnerLarry Solow - PartnerVivek Jain - CEO and ChairmanConference Call ParticipantsBrett Fishbin - VP and Senior Equity Research AnalystJason Bednar - Senior Research AnalystMike Matson - Senior AnalystOperatorGood day, and welcome to the ICU Medical, Inc., fourth quarter 2025 earnings conference call. All parti ...

PTC Therapeutics (NasdaqGS:PTCT) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Company ParticipantsEllen Cavaleri - Head of Investor RelationsEric Pauwels - Chief Business OfficerJarwei Fang - VP of Large-Cap Biotechnology and Pharma Equity ResearchJoe Heidt - Equity Research AssociateMatthew Klein - CEOPierre Gravier - CFOTazeen Ahmad - Managing DirectorConference Call ParticipantsBen Burnett - Executive Director and Senior Equity AnalystBrian Cheng - Executive Director and Senior Biotech AnalystElli ...

iRhythm Technologies (NasdaqGS:IRTC) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Company ParticipantsAllen Gong - VPDan Wilson - CFODavid Roman - Managing DirectorDavid Saxon - Managing DirectorJoanne Wuensch - Managing DirectorNathan Treybeck - Equity Research Vice PresidentQuentin Blackford - President and CEORichard Newitter - Managing DirectorStephanie Piazzola - VP of Equity Research Medical TechnologyStephanie Zhadkevich - Senior Director of Investor RelationsSuraj Kalia - Managing DirectorVij ...

AXT (NasdaqGS:AXTI) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Company ParticipantsGary Fischer - CFOLeslie Green - Investor RelationsMorris Young - CEOTim Bettles - VP of Business DevelopmentConference Call ParticipantsMatt Bryson - AnalystRichard Shannon - AnalystTim Savageaux - AnalystOperatorGood afternoon, everyone, and welcome to AXT's Q4 2025 financial conference call. Leading the call today is Dr. Morris Young, Chief Executive Officer, and Gary Fischer, Chief Financial Officer. In addition, ...

Alarm.com (NasdaqGS:ALRM) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Company ParticipantsAdam Hotchkiss - VP of Emerging Software and Equity ResearchAdam Tindle - Managing DirectorKevin Bradley - CFOMatthew Zartman - Vice President of Investor RelationsSaket Kalia - Managing DirectorSteve Trundle - CEOConference Call ParticipantsJack Vander Aarde - SVP and Senior Research Analyst of TMT, Gaming and EntertainmentSteven Sheldon - Research Analyst for Technology, Media, and CommunicationsNone - Analys ...

能有多大本事？ 马力全开启新程！ 订单排到了下半年 出口量翻倍增长 重点覆盖北美、欧洲等地区…… 春节期间"不打烊" 南京华信藤仓光通信有限公司内 大红灯笼高高挂 生产车间一派繁忙 加足马力赶进度、抓生产 全力冲刺"开门红"！ 拉丝塔顶，巨大的光纤预制棒缓缓降下； 塔身核心，直径200毫米、长约3米的光纤预制棒，被拉丝炉内2000多摄氏度的高温加热软化； 塔底，像是做"拉丝糖"一样，软化后的预制棒通过拉丝机"吐"出直径仅125微米、细若发丝的光纤…… 这么一根"玻璃丝" "传统通信光纤就像普通公路，数据像车辆各自择路而行——有的绕远，有的堵车，路径随机、时延不定；算力网络需要的是专用通道——准时发车、中 途不停、路径固定，速度快、时延低、传输稳定。"南京华信藤仓副总经理徐竞奕介绍，算力中心之间的海量数据调度，对光纤铺设时挤压、弯曲带来的 信号损耗、传输延迟极为敏感，而高强度抗微弯光纤，正是"追光者"们交出的创新答卷。 这种新型光纤，相当于把普通公路升级为高速专用通道，在受压、振动、微小弯折等情况下，信号损耗能降低约30%。千万别小看这30%。在繁忙的算力 网络中，这就是海量数据不拥塞、不排队、稳定高速传输的关 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________________________ FORM 10-K ________________________________________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHA ...

Travere Therapeutics (NasdaqGM:TVTX) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Speaker3Good afternoon, and welcome to the Travere Therapeutics fourth quarter and full year 2025 financial results conference call. Today's call is being recorded. At this time, I would like to turn the conference call over to Nivi Nehra, Vice President, Corporate Communications and Investor Relations. Please go ahead, Nivi.Speaker4Thank you, operator. Good afternoon, and welcome to Travere Therapeutics' fourth quarter ...

PTC Therapeutics (NasdaqGS:PTCT) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Speaker12Ladies and gentlemen, thank you for standing by. Welcome to PTC Therapeutics' fourth quarter and full year 2025 earnings conference call. All participants are in a listen-only mode. After the presentation, there will be a question-and-answer session. Today's conference is being recorded. I would now like to turn the conference over to Ellen Cavaleri, Head of Investor Relations. Please, please go ahead.Speaker2Good ...

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $23.0 million, down from $28.0 million in Q3 2025 and $25.1 million in Q4 2024 [4] - Non-GAAP gross margin in Q4 was 21.5%, compared to 22.6% in Q3 2025 and 18.0% in Q4 2024 [5] - Non-GAAP operating loss in Q4 2025 was $2.6 million, an increase from a loss of $384,000 in Q3 2025 and a loss of $5.4 million in Q4 2024 [6][7] - Cash and investments increased by $97.2 million to $128.4 million as of December 31, primarily due to a public offering [9] Business Line Data and Key Metrics Changes - Revenue from Indium Phosphide was $8.0 million, primarily from data center applications, while Gallium Arsenide generated $7.0 million [4] - Revenue from consolidated raw material joint ventures was $7.6 million in Q4 [4] - The backlog for indium phosphide wafers reached over $60 million, indicating strong demand [16] Market Data and Key Metrics Changes - Revenue from Asia Pacific accounted for 81.5% of total revenue, Europe 17.5%, and North America 1% [4] - Revenue related to the data center market in China is expected to grow by more than 60% in Q1 2026 compared to Q4 2025 [18] Company Strategy and Development Direction - The company plans to list its subsidiary, Tongmei, on the STAR Market in Shanghai, focusing on the growing demand for indium phosphide substrates in AI infrastructure [10] - AXT is expanding its capacity, aiming to double it by the end of 2026, with a focus on six-inch indium phosphide products [19][53] - The company is actively engaging with customers to understand their long-term requirements and align expansion plans globally [19] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment over the number of export permits received in Q4 but noted improvements in Q1 [14] - The company expects sequential revenue growth in Q1, driven by indium phosphide demand for AI data centers [15] - The geopolitical environment is affecting the export permit process, which remains a significant gating factor for growth [23] Other Important Information - The company is focused on improving gross margins, controlling operating expenses, and reducing inventory [24] - The management highlighted the importance of maintaining efficiency in operations to meet growing demand [23] Q&A Session Summary Question: Revenue number for the quarter - The company confirmed a revenue number of approximately $26 million for Q1, with potential upside if more permits are received [31][32] Question: Licensing process insights - The licensing process has become less predictable, with some permits being denied but with instructions for resubmission [40][41] Question: Backlog and customer ordering patterns - Customers are placing longer-term orders, with forecasts extending beyond 2030, indicating strong demand [50] Question: Capacity additions and CapEx requirements - The company plans to double its capacity by the end of 2026, requiring approximately $30 million for the initial phase [53] Question: Demand and shipment capabilities - If permits were not a constraint, the company could potentially ship $20 million worth of indium phosphide, with expectations to increase to $35 million by year-end [90][91]